Clinical Trial

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-18.
Status change: Not Yet Recruiting → Recruiting 2025-10-10
Trial Details
NCT Number NCT06940440
Lead Sponsor TuHURA Biosciences, Inc.
Conditions Advanced Or Metastatic Merkel Cell Carcinoma
Enrollment 9 participants
Start Date 2025-10
Primary Completion 2026-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-15